These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36614015)

  • 1. Organ Weights in
    Antipova V; Steinhoff LM; Holzmann C; Rolfs A; Hempel CJ; Witt M; Wree A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender-Specific Effects of Two Treatment Strategies in a Mouse Model of Niemann-Pick Disease Type C1.
    Holzmann C; Witt M; Rolfs A; Antipova V; Wree A
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33802605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic Treatment Assigned for Niemann Pick Type C1 Disease Partly Changes Behavioral Traits in Wild-Type Mice.
    Schlegel V; Thieme M; Holzmann C; Witt M; Grittner U; Rolfs A; Wree A
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced cerebellar neurodegeneration after combined therapy with cyclodextrin/allopregnanolone and miglustat in NPC1: a mouse model of Niemann-Pick type C1 disease.
    Maass F; Petersen J; Hovakimyan M; Schmitt O; Witt M; Hawlitschka A; Lukas J; Rolfs A; Wree A
    J Neurosci Res; 2015 Mar; 93(3):433-42. PubMed ID: 25400034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy with cyclodextrin/allopregnanolone and miglustat improves motor but not cognitive functions in Niemann-Pick Type C1 mice.
    Hovakimyan M; Maass F; Petersen J; Holzmann C; Witt M; Lukas J; Frech MJ; Hübner R; Rolfs A; Wree A
    Neuroscience; 2013 Nov; 252():201-11. PubMed ID: 23948640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1.
    Neßlauer AM; Gläser A; Gräler M; Engelmann R; Müller-Hilke B; Frank M; Burstein C; Rolfs A; Neidhardt J; Wree A; Witt M; Bräuer AU
    Lipids Health Dis; 2019 Jun; 18(1):146. PubMed ID: 31248418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in
    Hoque S; Kondo Y; Sakata N; Yamada Y; Fukaura M; Higashi T; Motoyama K; Arima H; Higaki K; Hayashi A; Komiya T; Ishitsuka Y; Irie T
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Two Liver Treatment Strategies in a Mouse Model of Niemann-Pick-Disease Type C1.
    Ebner L; Gläser A; Bräuer A; Witt M; Wree A; Rolfs A; Frank M; Vollmar B; Kuhla A
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Regenerative Capacity of the Olfactory Epithelium in Niemann-Pick Disease Type C1.
    Meyer A; Wree A; Günther R; Holzmann C; Schmitt O; Rolfs A; Witt M
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28383485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corneal alterations during combined therapy with cyclodextrin/allopregnanolone and miglustat in a knock-out mouse model of NPC1 disease.
    Hovakimyan M; Petersen J; Maass F; Reichard M; Witt M; Lukas J; Stachs O; Guthoff R; Rolfs A; Wree A
    PLoS One; 2011; 6(12):e28418. PubMed ID: 22163015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual evoked potentials of Niemann-Pick type C1 mice reveal an impairment of the visual pathway that is rescued by 2-hydroxypropyl-ß-cyclodextrin.
    Palladino G; Loizzo S; Fortuna A; Canterini S; Palombi F; Erickson RP; Mangia F; Fiorenza MT
    Orphanet J Rare Dis; 2015 Oct; 10():133. PubMed ID: 26458950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different Trafficking Phenotypes of Niemann-Pick C1 Gene Mutations Correlate with Various Alterations in Lipid Storage, Membrane Composition and Miglustat Amenability.
    Brogden G; Shammas H; Walters F; Maalouf K; Das AM; Naim HY; Rizk S
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32204338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic administration of 2-hydroxypropyl-β-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function.
    Lopez AM; Terpack SJ; Posey KS; Liu B; Ramirez CM; Turley SD
    Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):780-7. PubMed ID: 25115571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling.
    Fan M; Sidhu R; Fujiwara H; Tortelli B; Zhang J; Davidson C; Walkley SU; Bagel JH; Vite C; Yanjanin NM; Porter FD; Schaffer JE; Ory DS
    J Lipid Res; 2013 Oct; 54(10):2800-14. PubMed ID: 23881911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-Pick disease type C1 mice.
    Williams IM; Wallom KL; Smith DA; Al Eisa N; Smith C; Platt FM
    Neurobiol Dis; 2014 Jul; 67():9-17. PubMed ID: 24631719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.
    Davidson CD; Ali NF; Micsenyi MC; Stephney G; Renault S; Dobrenis K; Ory DS; Vanier MT; Walkley SU
    PLoS One; 2009 Sep; 4(9):e6951. PubMed ID: 19750228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Brain-Specific Treatment Effects in NPC1 Disease by Focusing on Cellular and Molecular Changes of Sphingosine-1-Phosphate Metabolism.
    Gläser A; Hammerl F; Gräler MH; Coldewey SM; Völkner C; Frech MJ; Yang F; Luo J; Tönnies E; von Bohlen Und Halbach O; Brandt N; Heimes D; Neßlauer AM; Korenke GC; Owczarek-Lipska M; Neidhardt J; Rolfs A; Wree A; Witt M; Bräuer AU
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered transition metal homeostasis in Niemann-Pick disease, type C1.
    Hung YH; Faux NG; Killilea DW; Yanjanin N; Firnkes S; Volitakis I; Ganio G; Walterfang M; Hastings C; Porter FD; Ory DS; Bush AI
    Metallomics; 2014 Mar; 6(3):542-53. PubMed ID: 24343124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of glutamate neurotoxicity: A novel therapeutic approach for Niemann-Pick disease, type C1.
    Cougnoux A; Yerger JC; Fellmeth M; Serra-Vinardell J; Navid F; Wassif CA; Cawley NX; Porter FD
    Mol Genet Metab; 2021 Dec; 134(4):330-336. PubMed ID: 34802899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ontogenesis and Modulation of Intestinal Unesterified Cholesterol Sequestration in a Mouse Model of Niemann-Pick C1 Disease.
    Lopez AM; Ramirez CM; Taylor AM; Jones RD; Repa JJ; Turley SD
    Dig Dis Sci; 2020 Jan; 65(1):158-167. PubMed ID: 31312996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.